Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1052595-22-8

Post Buying Request

1052595-22-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1052595-22-8 Usage

General Description

1-Phenyl-5-pyridin-3-yl-1H-pyrazole-3-carboxylic acid is a chemical compound with a complex structure consisting of a phenyl group, a pyridinyl group, and a pyrazolecarboxylic acid group. It is known for its potential use in pharmaceutical research and drug development due to its structure and properties, which make it suitable for various biological activities. The compound may have potential applications in the development of new drugs for the treatment of certain diseases or conditions, and it could also be used in research studies to understand the interactions of similar chemical structures with biological systems. Its unique structure and properties make it an interesting compound for further research and potential therapeutic applications.

Check Digit Verification of cas no

The CAS Registry Mumber 1052595-22-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,2,5,9 and 5 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1052595-22:
(9*1)+(8*0)+(7*5)+(6*2)+(5*5)+(4*9)+(3*5)+(2*2)+(1*2)=138
138 % 10 = 8
So 1052595-22-8 is a valid CAS Registry Number.

1052595-22-8Downstream Products

1052595-22-8Relevant articles and documents

Design, synthesis and biological screening of some pyridinylpyrazole and pyridinylisoxazole derivatives as potential anti-inflammatory, analgesic, antipyretic and antimicrobial agents

El-Hawash, Soad A.M.,Soliman, Raafat,Youssef, Amal M.,Ragab, Hanan M.A.,Elzahhar, Perihan A.S.,El-Ashmawey, Ibrahim M.,Wahab, Abeer E. Abdel,Shaat, Iman A.

, p. 318 - 338 (2014/05/06)

A series of substituted pyridinylpyrazole (or isoxazole) derivatives was synthesized and evaluated for their antiinflammatory (AI) activity using formalin-induced paw edema bioassays. The inhibitory activities of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) were also determined. The analgesic activity of the same compounds was evaluated using rat-tail withdrawal technique. Their antipyretic activity was also evaluated. The results revealed that compounds 4a,b, 6a, 8a, 14c and 15a exhibited significant AI and analgesic activities. Compounds 5a, 6a and 8a displayed good antipyretic activity. Compounds 14c and 15a showed good COX-2 inhibitory activity and weak inhibition of COX- 1. Additionally, the most active compounds were shown to have a large safety margin (ALD50 >300-400 mg/Kg) and minimal ulcerogenic potentialities when administered orally at a dose of 300 mg/Kg. Docking studies for 14c and 15a with COX-2 showed good binding profile. Antimicrobial evaluation proved that most of the compounds exhibited distinctive activity against the gram negative bacteria, P. aeruginosa and E coli.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1052595-22-8